TY  - GEN 
AU  - Lampertico, P.
AU  - Carrion, J. A.
AU  - Curry, M.
AU  - Turnes Vázquez, Juan
AU  - Cornberg, M.
AU  - Negro, F.
AU  - Brown, A.
AU  - Persico, M.
AU  - Wick, N.
AU  - Porcalla, A.
AU  - Pangerl, A.
AU  - Crown, E.
AU  - Larsen, L.
AU  - Yu, Y.
AU  - Wedemeyer, H.
PY  - 2020
SN  - 0168-8278
UR  - http://hdl.handle.net/20.500.11940/16358
AB  - BACKGROUND & AIMS: Glecaprevir/pibrentasvir is approved for treating adults infected with HCV genotypes 1-6. In clinical trials, glecaprevir/pibrentasvir was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12)...
KW  - Quinoxalines
KW  - Drug Combinations
KW  - Adult
KW  - Middle Aged
KW  - Headache
KW  - Benzimidazoles
KW  - Sulfonamides
KW  - Adolescent
KW  - Fatigue
KW  - Pyrrolidines
KW  - Hepatitis C
KW  - Humans
KW  - Young Adult
KW  - Pruritus
KW  - Hepacivirus
KW  - Aged
KW  - Antiviral Agents
KW  - Cohort Studies
TI  - Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis
DO  - 10.1016/j.jhep.2020.01.025
KW  - CHUP
VL  - 72
ER  -